New hope for bile duct cancer: experimental combo targets tough tumors
NCT ID NCT05849480
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (CDX-1140) combined with three other cancer drugs for people with advanced biliary tract cancer that has spread or come back after treatment. About 60 adults will receive the drugs through an IV and a pill over 21-day cycles for up to 2 years. The goal is to find a safe dose and see if the combination can shrink tumors or slow the cancer's growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILE DUCT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemotherapy sprayed directly into the abdomen: a new attack on stubborn cancers
- Zapping spreading tumors could extend life on current cancer drugs
- Music may soothe pain at the genetic level after cancer surgery
- New combo therapy for bile duct cancer enters safety trial
- New drug combo tested for tough bile duct cancers
- Triple therapy shrinks bile duct tumors, may enable surgery